...
首页> 外文期刊>European journal of clinical pharmacology >Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.
【24h】

Antihypertensive effects exerted by enalapril in mild to moderate hypertension are not associated with changes in the circulating levels of nitric oxide-related markers.

机译:依那普利在轻度至中度高血压中产生的降压作用与一氧化氮相关标志物的循环水平变化无关。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: The antihypertensive effects of angiotensin-converting enzyme inhibitors (ACEi) are explained, at least in part, by enhanced bradykinin-dependent nitric oxide (NO) formation and decreased angiotensin II-induced oxidative stress and vasoconstriction. We examined for the first time whether treatment with enalapril increases the plasma levels of markers of NO formation and decreases oxidative stress in mild to moderate hypertensive patients. METHODS: Eighteen untreated hypertensive patients were treated with enalapril 10 mg/day (n=10) or 20 mg/day (n=8) for 60 days. Eighteen normotensive healthy controls were followed for the same period. Venous blood samples were collected at baseline and after 30/60 days of treatment with enalapril. Plasma NOx (nitrites + nitrates) concentrations were determined by using the Griess reaction. Plasma nitrite and whole blood nitrite concentrations were determined by using an ozone-based chemiluminescence assay. Plasma thiobarbituric acid-reactive species (TBARS) and 8-isoprostane concentrations were determined by a fluorimetric method and by ELISA, respectively. RESULTS: Treatment with enalapril decreased blood pressure in hypertensive patients. However, we found no significant changes in plasma NOx, nitrite, whole blood nitrite, and in the levels of markers of oxidative stress in both normotensive controls and hypertensive patients treated with enalapril. CONCLUSIONS: Our data show that enalapril 10-20 mg/day does not affect the concentrations of relevant markers of NO formation or markers of oxidative stress in mild to moderately hypertensive subjects, despite satisfactory blood pressure control. Our findings do not rule out the possibility that ACEi may produce such effects in more severely hypertensive patients treated with higher doses of ACEi.
机译:目的:血管紧张素转换酶抑制剂(ACEi)的降压作用至少部分是通过增强缓激肽依赖性一氧化氮(NO)的形成和降低血管紧张素II诱导的氧化应激和血管收缩来解释的。我们首次检查了依那普利治疗是否可增加轻度至中度高血压患者的血浆NO形成水平并降低氧化应激。方法:十八名未经治疗的高血压患者接受依那普利10 mg /天(n = 10)或20 mg /天(n = 8)治疗60天。同期随访十八名正常血压健康对照者。在基线和使用依那普利治疗30/60天后收集静脉血样。使用Griess反应测定血浆NOx(亚硝酸盐+硝酸盐)浓度。使用基于臭氧的化学发光测定法测定血浆亚硝酸盐和全血亚硝酸盐的浓度。血浆硫代巴比妥酸反应性物质(TBARS)和8-异前列腺素浓度分别通过荧光法和ELISA测定。结果:依那普利治疗可降低高血压患者的血压。然而,我们发现在血压正常对照和接受依那普利治疗的高血压患者中,血浆NOx,亚硝酸盐,全血亚硝酸盐以及氧化应激指标水平均无显着变化。结论:我们的数据显示,尽管血压控制良好,但依那普利10-20 mg /天对轻度至中度高血压受试者的NO形成相关标志物或氧化应激标志物的浓度没有影响。我们的发现不排除ACEi在使用较高剂量ACEi治疗的更严重的高血压患者中可能产生这种作用的可能性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号